Sarepta Therapeutics (NASDAQ:SRPT) Price Target Lowered to $28.00 at JPMorgan Chase & Co.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) had its price objective lowered by analysts at JPMorgan Chase & Co. from $30.00 to $28.00 in a report released on Thursday,Benzinga reports. The brokerage presently has an "overweight" rating on the biotechnology company's stock. JPMorgan Chase & Co.'s target price would indicate a potential upside of 46.83% from the company's current price.

Other analysts have also issued reports about the stock. Royal Bank Of Canada decreased their target price on shares of Sarepta Therapeutics from $87.00 to $58.00 and set a "sector perform" rating on the stock in a research report on Wednesday, May 7th. UBS Group reduced their target price on shares of Sarepta Therapeutics from $188.00 to $85.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. Guggenheim cut their price target on Sarepta Therapeutics from $112.00 to $98.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Evercore ISI lowered shares of Sarepta Therapeutics from an "outperform" rating to an "inline" rating and set a $50.00 target price on the stock. in a report on Thursday, May 8th. Finally, Mizuho lowered their price objective on shares of Sarepta Therapeutics from $85.00 to $40.00 and set an "outperform" rating for the company in a research report on Wednesday, June 18th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $58.54.

Sarepta Therapeutics Stock Performance

SRPT traded down $0.30 on Thursday, hitting $19.07. 3,085,755 shares of the company's stock were exchanged, compared to its average volume of 2,230,390. The stock has a fifty day moving average of $32.76 and a two-hundred day moving average of $73.33. Sarepta Therapeutics has a twelve month low of $16.88 and a twelve month high of $154.13. The firm has a market cap of $1.87 billion, a PE ratio of -7.09 and a beta of 0.45. The company has a current ratio of 4.02, a quick ratio of 2.46 and a debt-to-equity ratio of 1.00.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). Sarepta Therapeutics had a negative return on equity of 14.88% and a negative net margin of 11.12%. The business had revenue of $744.86 million for the quarter, compared to the consensus estimate of $685.75 million. During the same quarter in the previous year, the business posted $0.73 earnings per share. The company's quarterly revenue was up 80.2% on a year-over-year basis. On average, research analysts anticipate that Sarepta Therapeutics will post 2.67 earnings per share for the current fiscal year.

Institutional Trading of Sarepta Therapeutics

A number of institutional investors have recently bought and sold shares of SRPT. Jones Financial Companies Lllp lifted its holdings in Sarepta Therapeutics by 274.5% in the fourth quarter. Jones Financial Companies Lllp now owns 528 shares of the biotechnology company's stock valued at $64,000 after acquiring an additional 387 shares during the period. Steward Partners Investment Advisory LLC raised its position in Sarepta Therapeutics by 164.4% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock valued at $38,000 after purchasing an additional 194 shares in the last quarter. Victory Capital Management Inc. raised its position in Sarepta Therapeutics by 34.0% in the 4th quarter. Victory Capital Management Inc. now owns 88,808 shares of the biotechnology company's stock valued at $10,798,000 after purchasing an additional 22,529 shares in the last quarter. Proficio Capital Partners LLC acquired a new stake in shares of Sarepta Therapeutics during the 4th quarter worth about $3,829,000. Finally, PNC Financial Services Group Inc. lifted its stake in Sarepta Therapeutics by 5.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,891 shares of the biotechnology company's stock valued at $352,000 after buying an additional 145 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.